The drug Fervex is used for diseases caused by acute respiratory infections, as well as rhinopharyngitis, to alleviate the general condition of the patient and the development of the following symptoms:
With increased formation of mucus in the nasal region, as well as with a feeling of nasal congestion.
With increased body temperature of the patient.
When lacrimation and sneezing occur due to acute respiratory infections.
The following situations are contraindications for the use of the drug Fervex:
The presence of hypersensitivity or individual intolerance to the components that are included in the composition of the medicinal product.
The presence of lesions of the gastrointestinal tract of an erosive and ulcerative type of an acute nature.
Pathology of the functional activity of the liver.
The presence of angle-closure glaucoma.
Pathologies of the functions of the prostate and urinary system, causing a delay in the urination process.
The presence of portal type hypertension.
Alcohol abuse and alcoholism.
The presence of hereditary diseases (phenylketonuria), belonging to the group of fermentopathies, which is caused by a violation of amino acid metabolic processes (in particular phenylalanine).
The period of pregnancy, since there is no data on clinical trials confirming the safety of Fervex for fetal development and the health of the expectant mother.
The period of breastfeeding, since there are no data on clinical trials confirming the safety of Fervex for the health of the baby.
Age indicators up to fifteen years.
With extreme caution, therapy with Fervex is carried out in the presence of congenital pathologies associated with hyperbilirubinemia, with hepatitis of a viral or alcoholic nature, as well as in the elderly patient.
Typically, Fervex is well tolerated, however, when conducting a therapeutic course, the following negative manifestations of side effects may develop:
Digestive system. It may cause nausea, indigestion, soreness in the epigastric region, and dry mouth. When conducting therapy at a dosage significantly exceeding the maximum therapeutic dose, the development of liver function disorders is possible.
Hematopoietic system. In rare cases, the development of anemia, thrombocytopenia and methemoglobinemia is possible.
Urinary system. In rare cases, urinary retention may develop. When conducting therapy in a dosage significantly exceeding the maximum therapeutic dose, the development of renal function impairment is possible.
The immune system. Allergic reactions may occur, manifested in the form of a rash, itching, redness of the skin, as well as angioedema.
The cardiovascular system. Perhaps the development of a feeling of palpitations, dizziness, a disorder of coordination functions, a nebula of consciousness. As well as disorders of concentration functions (more often in elderly patients).
Miscellanea. In rare cases, the development of paresis of accommodation, as well as the occurrence of drowsiness, is possible.
In case of development of negative manifestations, it is necessary to interrupt therapy and seek the advice of a specialist doctor.
Fervex is used orally.
The standard dosage is one sachet twice - three times a day.
The powder contained in the bag must be dissolved in a glass of boiled and cooled water.
The maximum daily dosage is 4 grams of active substance (eight sachets) with a patient weighing more than fifty kilograms.
The duration of the therapeutic course is not recommended for more than five days.
The interval between uses is recommended to observe at least four hours. With pathologies of renal functions (creatinine clearance less than 10 ml/min), the interval for using Fervex should be increased to eight hours or more.
If during the treatment for five days there is no relief of the patient's condition, then therapy should be discontinued and a specialist doctor should be consulted.
In case of an overdose, acute poisoning may develop, manifested in the following symptoms: a complete lack of appetite (anorexia), a feeling of nausea, pain in the epigastric region, increased sweating, blanching of the skin, drowsiness. After a few days, it is possible to develop damage to the liver. In severe overdose, manifestations of liver failure, hepatonecrosis, encephalopathy, convulsive symptoms and, in extreme cases, a coma that can lead to the death of the patient may develop.
In case of an overdose, discontinue therapy with Fervex immediately and consult a specialist doctor for help.
For treatment, gastric lavage, the use of enterosorbents, and the use of an antidote, acetylcysteine, should be performed.
In the future, symptomatic therapy is performed.
Fervex is available in several varieties, with and without sugar, for patients with diabetic diseases it is necessary to carefully look at the composition of the product.
The simultaneous use of Fervex with agents containing paracetamol is not recommended, since this can cause hepatotoxic effects.
In the case of therapy with an increased dosage of Fervex, mental dependence may occur. To avoid overdose, it is necessary to take into account the amount of substance taken per day, which should not exceed four grams.
If it is necessary to use concomitant use with metoclopramide, domperidone and cholestyramine before starting therapy, you should consult a specialist doctor.
When conducting drug therapy, distortion of indicators obtained during clinical trials to determine the level of urea and glucose in the blood may occur.
The use of a medical device may cause hepatotoxic side effects in alcoholic hepatosis.
When conducting a long period of therapy at elevated dosages, blood tests should be monitored.
The simultaneous use with preparations containing ethanol increases the sedative effect of antihistamines, in particular pheniramine. It can also contribute to the occurrence of acute inflammatory processes in the pancreas (pancreatitis).
The simultaneous use of the drug Fervex with morphine derivatives, barbiturates, benzodiazepines, antipsychotics, anti-depressants, sedatives, included in the group of n1-blockers enhances the sedative effectiveness of these drugs and increases the likelihood of developing negative effects (delay urination, dry mouth cavities, constipation).
It is also necessary to take into account the possibility of developing manifestations of a central atropine-like type in the case of simultaneous use with drugs that have anticholinergic effects, in particular with antihistamines; antidepressant substances in the imipramine group; antipsychotics belonging to the phenothiazine series; drugs with activity against Parkinson's disease; as well as antispasmodics of the atropine-like type and disopyramide.
In the case of complex therapy of the drug, Fervex with agents exhibiting the properties of activating the oxidation of microsomes, in particular barbiturate substances, tricyclic antidepressants, drugs exhibiting an anticonvulsant effect, as well as rifampicin, ethanol, flumecinol and phenylbutazone, the likelihood of developing hepatoxic effects increases.
Concomitant use with glucocorticosteroids increases the possibility of glaucoma.
Conducting joint therapy with substances included in the group of salicylates increases the possibility of nephrotoxicity.
With simultaneous use with anticoagulant agents, their effectiveness increases.
Combined therapy with drugs with uricosuric effect, their effectiveness decreases.
Since there is currently no reliable information on the results of clinical trials in pregnant patients, it is not recommended to use the drug in this group of people.
If you need to use Fervex medication during lactation, it is recommended to interrupt breastfeeding.
During the therapeutic course, Fervex may develop negative manifestations of side effects, expressed in dizziness, drowsiness, and loss of coordination. It is not recommended to control technical means and work with high-precision mechanisms throughout the course of therapy.
It is forbidden to drink alcohol during medical treatment, as this can serve as a reason for the development of hepatoxicity and other liver pathologies.
Storage of the drug Fervex must be carried out at a temperature of from fifteen to twenty-five degrees. Subject to storage rules, the shelf life is thirty-six months.